본문 바로가기
KERD
논문KCI 등재

한국인 만성 C형간염에서 페그인터페론 알파와 리바비린 또는 인터페론 알파와 리바비린의 병합요법: 치료기간에 따른 성적 비교

Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C

문희정|은종렬|최재원|이헌주|김경옥
대한간학회 (The korean Association for the Study of the Liver)|2008.03|Clinical and Molecular Hepatology|제14권 제1호|pp. 46-57

3

조회

0

다운로드

7

인용

0

참고문헌

초록

Background/Aims: This study compared the efficacy and safety of combined peginterferon alfa (PEG-IFN) and ribavirin with that of combined interferon alpha (IFN-α) and ribavirin, according to the treatment duration in Korean patients with chronic hepatitis C. Methods: Medical records of 86 patients treated with PEG-IFN and ribavirin (mean age, 50.7 years; males/females, 57/29; genotypes 1/2, 59/27) and 134 patients treated with IFN-α and ribavirin (mean age, 50.9 years; males/females 74/60; genotypes 1/2, 79/55) were reviewed. Ribavirin was administered at doses of 600-1,200 mg and 600-800 mg in patients with genotypes 1 and 2, respectively. Results: Sustained virological responses (SVRs) were evident in 68.4% and 41.7% of genotype 1 patients treated for 48 weeks in the PEG-IFN and IFN-α groups, respectively (P=0.021), and in 94.1% and 64.9% of genotype 2 patients treated for 24 weeks (P=0.026). Some genotype 1 patients treated for 24 weeks in the PEG-IFN group, who all exhibited negative HCV PCR results at week 12, showed an SVR of 87.5% (7/8). Conclusions: The rate of SVRs in Korean patients with chronic hepatitis C was higher for combined PEG-IFN and ribavirin than for combined IFN-α and ribavirin. Further study is needed to clarify the outcome of short-term therapy in patients with a rapid or early virological response.

Abstract

Background/Aims: This study compared the efficacy and safety of combined peginterferon alfa (PEG-IFN) and ribavirin with that of combined interferon alpha (IFN-α) and ribavirin, according to the treatment duration in Korean patients with chronic hepatitis C. Methods: Medical records of 86 patients treated with PEG-IFN and ribavirin (mean age, 50.7 years; males/females, 57/29; genotypes 1/2, 59/27) and 134 patients treated with IFN-α and ribavirin (mean age, 50.9 years; males/females 74/60; genotypes 1/2, 79/55) were reviewed. Ribavirin was administered at doses of 600-1,200 mg and 600-800 mg in patients with genotypes 1 and 2, respectively. Results: Sustained virological responses (SVRs) were evident in 68.4% and 41.7% of genotype 1 patients treated for 48 weeks in the PEG-IFN and IFN-α groups, respectively (P=0.021), and in 94.1% and 64.9% of genotype 2 patients treated for 24 weeks (P=0.026). Some genotype 1 patients treated for 24 weeks in the PEG-IFN group, who all exhibited negative HCV PCR results at week 12, showed an SVR of 87.5% (7/8). Conclusions: The rate of SVRs in Korean patients with chronic hepatitis C was higher for combined PEG-IFN and ribavirin than for combined IFN-α and ribavirin. Further study is needed to clarify the outcome of short-term therapy in patients with a rapid or early virological response.

참고문헌 (34)

  1. Global surveillance and control of hepatitis C, "Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium", J Viral Hepat, 6, pp.35~47 (1999)
  2. Pawlotsky JM, "Therapy of hepatitis C: from empiricism to eradication", Hepatology, 43(Suppl), pp.207~220 (2006)
  3. Han SW, "A study on positive rate of anti-HCV in Korean adults", Kor J Med, 47, pp.744~750 (1994)
  4. Han KH, "Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C", Korean J Hepatol, 10, pp.81~87 (2004)
  5. Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
  6. Hadziyannis SJ, "Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
  7. Lee H, "Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea", Korean J Hepatol, 12, pp.31~40 (2006)
  8. Treatment guidelines for chronic hepatitis C, "The Korean association for the study of the liver", Korean J Hepatol, 10(Suppl), pp.101~125 (2004)
  9. Jensen DM, "Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40kD)", ribavirin therapy, 2006, pp.43, 954~960
  10. Yu ML, "A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C", Gut, 56, pp.553~559 (2007)
  11. Hwang SY, "Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C", Korean J Gastroenterol, 49, pp.166~172 (2007)
  12. Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
  13. Di Bisceglie AM, "Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double- blind, placebo-controlled trial", N Engl J Med, 321, pp.1506~1510 (1989)
  14. McHutchison JG, "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C", N Engl J Med, 339, pp.1485~1492 (1998)
  15. Xie Y, "Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial", Hepatobiliary Pancreat Dis Int, 4, pp.213~219 (2005)
  16. Mangia A, "Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3", N Engl J Med, 352, pp.2609~2617 (2005)
  17. von Wagner M, "Peginterferon alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C", Gastroenterology, 129, pp.522~527 (2005)
  18. Dalgard O, "Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study", Hepatology, 40, pp.1260~1265 (2004)
  19. Mangia A, "Short-duration therapy for hepatitis C: suitable for all?", J Viral Hepat, 14, pp.221~227 (2007)
  20. Okanoue T, "Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients", J Hepatol, 30, pp.653~659 (1999)
  21. Kato J, "Normalization of elevated hepatic 8-hydroxy-2’-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet", Cancer Res, 61, pp.8697~8702 (2001)
  22. Kaito M, "Iron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C", J Gastroenterol, 41, pp.921~922 (2006)
  23. Sarisky RT, "Non-nucleoside inhibitors of the HCV polymerase", J Antimicrob Chemother, 54, pp.14~16 (2004)
  24. Neyts J, "Selective inhibitors of hepatitis C virus replication", Antiviral Res, 71, pp.363~371 (2006)
  25. Huang Z, "Recent development of therapeutics for chronic HCV infection", Antiviral Res, 71, pp.351~362 (2006)
  26. Vogel W, "Peginterferon-alpha 2a (40kDa)", ribavirin combination for the treatment of chronic hepatitis C infection, 2003, pp.1, 423~431
  27. Kinzie JL, "African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians", J Viral Hepat, 8, pp.264~269 (2001)
  28. Hu KQ, "Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States", J Hepatol, 40, pp.147~154 (2004)
  29. Antúnez I, "Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C", P R Health Sci J, 23, pp.57~60 (2004)
  30. Soresi M, "Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis", Liver Int, 26, pp.1119~1125 (2006)
  31. Kara B, "Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection", Adv Ther, 24, pp.972~982 (2007)
  32. Lok AS, "Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial", Clin Gastroenterol Hepatol, 5, pp.245~254 (2007)
  33. Jacobson IM, "A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C", Am J Gastroenterol, 100, pp.2453~2462 (2005)
  34. Hu KQ, "Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans", Dig Dis Sci, 52, pp.570~578 (2007)

관련 논문AI추천

우리나라 만성 C형간염 환자에서 페그인터페론과 리바비린의 병합치료에 대한 효과강명주, 김지현, 박상원, 박성재, 박은택, 설상영, 이상혁, 이연재, 정은욱, 최바울대한간학회 · Clinical and Molecular Hepatology2008 · 제14권 제3호만성 C형간염에서 인터페론/페그인터페론과 리바비린 병합요법 후 지속바이러스반응 유지에 대한 고찰정석, 권계숙, 김영수, 김철현, 김형길, 박병도, 신용운, 이돈행, 이정일, 이진우대한간학회 · Clinical and Molecular Hepatology2009 · 제15권 제1호대전과 충청남북도에 거주하는 만성 C형간염 환자에서 페그인터페론 알파 2a와 2b의 초치료 효과 비교강영우, 김석배, 김석현, 김안나, 김정일, 김홍수, 남순우, 박병출, 박지영, 송일한, 이병석, 이태희, 이향이, 이헌영, 채희복대한간학회 · Clinical and Molecular Hepatology2008 · 제14권 제4호Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C임선영, 최혁순, Chang Ho Jung, Hoon Jai Chun, Hyung Joon Yim, Sang Jun Suh, Soon Ho Um, Tae Hyung Kim, Yeon Seok Seo거트앤리버 소화기연관학회협의회 · Gut and Liver2016 · 제10권 제5호만성 C형간염에서 페그인터페론과 리바비린 병합요법의 효과김민지, 노명환, 백양현, 윤현아, 이성욱, 이종훈, 장진석대한간학회 · Clinical and Molecular Hepatology2008 · 제14권 제1호Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea고광철, 곽금연, 백승운, 백용한, 유병철, 이준혁, 조현진, 최문석거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제5호

이 간행물의 다른 논문 (8건)

제주 지역 만성 C형간질환 환자의 유전자형의 분포현소영, 이호준, 송병철, 김흥업, 김광식, 김현주, 정승욱, 강동구, 최은광, 조유경pp. 28-35만성 C형간염에서 페그인터페론과 리바비린 병합요법의 효과김민지, 이성욱, 장진석, 이종훈, 노명환, 백양현, 윤현아pp. 36-45라미부딘 내성 만성 B형간염 환자에서 아데포비어 투여에 따른 내성 바이러스 출현 및 초기 바이러스반응에 미치는 인자김수옥, 유왕돈, 조성원, 조진희, 이명희, 박진선, 강준구, 홍선표, 정재연, 임남규pp. 58-66HBsAg 음성, anti-HCV 음성인 알코올간경변증에서 anti-HBc 양성 혹은 B형간염바이러스 잠재감염이 간세포암종 발생에 미치는 영향김유경, 권오상, 이서영, 정혁상, 김민주, 박동균, 김주현, 김연수, 정낙소, 구양서pp. 67-76심혈관계 위험인자로서의 비알코올지방간질환; 경동맥 동맥경화와의 상관관계강진화, 김영선, 박민정, 김동희, 임선희, 이효석, 최수연, 김충현pp. 77-88
원문 보기